Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response.

Characteristics and treatment outcomes among HIV-infected individuals in the Australian Trial in Acute Hepatitis C. Clin Infect Dis (2009) 2.68

Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology (2010) 2.56

Management of chronic hepatitis C: consensus guidelines. Can J Gastroenterol (2007) 2.06

Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology (2009) 1.99

Early interferon therapy for hepatitis C virus infection rescues polyfunctional, long-lived CD8+ memory T cells. J Virol (2008) 1.90

Early treatment improves outcomes in acute hepatitis C virus infection: a meta-analysis. J Viral Hepat (2009) 1.75

Testing strategy to identify cases of acute hepatitis C virus (HCV) infection and to project HCV incidence rates. J Clin Microbiol (2007) 1.70

Outcome of a hepatitis C outbreak among patients in a pain management clinic. Dig Dis Sci (2010) 1.43

Acute hepatitis C virus infection: a chronic problem. Hepatology (2008) 1.15

KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol (2016) 1.15

Treatment of hepatitis C as prevention: a modeling case study in Vietnam. PLoS One (2012) 1.09

Treatment failure in hepatitis C: mechanisms of non-response. J Hepatol (2008) 1.02

Novel strategy for treatment of viral central nervous system infection by using a cell-permeating inhibitor of c-Jun N-terminal kinase. J Virol (2007) 1.01

Current status and future directions in the management of chronic hepatitis C. Virol J (2012) 0.99

KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol (2014) 0.99

Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users. J Hepatol (2010) 0.98

The importance of implementing safe sharps practices in the laboratory setting in Europe. Biochem Med (Zagreb) (2014) 0.98

Hepatitis C: a clinical review. Oral Dis (2008) 0.94

Incidence and risk factors for newly acquired hepatitis C virus infection among Aboriginal versus non-Aboriginal Canadians in six regions, 1999-2004. Eur J Clin Microbiol Infect Dis (2007) 0.92

Candidate hepatitis C vaccine trials and people who inject drugs: challenges and opportunities. Vaccine (2010) 0.91

Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents. Hepat Med (2014) 0.89

Treatment of hepatitis C virus infection. World J Gastroenterol (2007) 0.87

Costs and cost-effectiveness of different follow-up schedules for detection of occupational hepatitis C virus infection. Gut (2008) 0.85

Differential alteration of CD56(bright) and CD56 (dim) natural killer cells in frequency, phenotype, and cytokine response in chronic hepatitis C virus infection. J Gastroenterol (2011) 0.85

Virological responses during treatment for recent hepatitis C virus: potential benefit for ribavirin use in HCV/HIV co-infection. AIDS (2012) 0.84

Clinical characteristics, spontaneous clearance and treatment outcome of acute hepatitis C: a single tertiary center experience. Saudi J Gastroenterol (2013) 0.84

Comparison of Hepatitis C Virus RNA and antibody detection in dried blood spots and plasma specimens. J Clin Virol (2014) 0.84

Symptomatic acute hepatitis C in Egypt: diagnosis, spontaneous viral clearance, and delayed treatment with 12 weeks of pegylated interferon alfa-2a. PLoS One (2008) 0.84

TARGETING THE NS5A PROTEIN OF HCV: AN EMERGING OPTION. Drugs Future (2011) 0.83

Analysis of the virus dynamics model reveals that early treatment of HCV infection may lead to the sustained virological response. PLoS One (2012) 0.82

SASLT practice guidelines: management of hepatitis C virus infection. Saudi J Gastroenterol (2012) 0.80

Inhibition of HCV by the serpin antithrombin III. Virol J (2012) 0.80

Developing and validating a scoring tool for identifying people who inject drugs at increased risk of hepatitis C virus infection. BMJ Open (2012) 0.78

Maintenance of Th1 hepatitis C virus (HCV)-specific responses in individuals with acute HCV who achieve sustained virological clearance after treatment. J Gastroenterol Hepatol (2013) 0.78

Making the best of a bad situation: early chronic nosocomial HCV infection. Dig Dis Sci (2010) 0.77

Distinct features in natural history and outcomes of acute hepatitis C. J Clin Gastroenterol (2015) 0.76

Treatment optimization for HIV/HCV co-infected patients. Ther Adv Infect Dis (2016) 0.75

Treatment of acute hepatitis C-how to explain the differences? Gastroenterology (2006) 0.75

Validation of EGCRISC for Chronic Hepatitis C Infection Screening and Risk Assessment in the Egyptian Population. PLoS One (2016) 0.75

Controversies in and challenges to our understanding of hepatitis C. World J Gastroenterol (2007) 0.75

Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology (2006) 0.75

Acute hepatitis C: prospects and challenges. World J Gastroenterol (2007) 0.75

Management of hepatitis c genotype 4 in the liver transplant setting. Saudi J Gastroenterol (2016) 0.75

Predictors of spontaneous viral clearance and outcomes of acute hepatitis C infection. Clin Mol Hepatol (2014) 0.75

The clinical course of acute hepatitis C. Dig Dis Sci (2014) 0.75

Telaprevir for previously treated chronic HCV infection. N Engl J Med (2010) 8.33

Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med (2004) 7.67

Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med (2011) 6.31

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology (2010) 6.14

Liver cirrhosis. Lancet (2008) 6.11

Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med (2007) 6.11

Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med (2007) 5.13

Exceeding the limits of liver histology markers. J Hepatol (2008) 5.06

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis (2013) 3.30

Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. J Hepatol (2005) 2.64

Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology (2006) 2.62

Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol (2009) 2.39

Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS (2005) 2.34

Diagnosis and quantitation of fibrosis. Gastroenterology (2008) 2.20

Effects of anti-viral therapy and HCV clearance on cerebral metabolism and cognition. J Hepatol (2011) 2.20

Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology (2005) 2.19

Duration of peginterferon therapy in acute hepatitis C: a randomized trial. Hepatology (2006) 2.11

Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. Gastroenterology (2010) 2.06

Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS (2007) 1.92

Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. Gastroenterology (2010) 1.74

Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. Hepatology (2007) 1.73

The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol (2007) 1.73

Helicobacter pylori moves through mucus by reducing mucin viscoelasticity. Proc Natl Acad Sci U S A (2009) 1.64

Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial. Gastroenterology (2013) 1.63

Circulating microRNAs as biomarkers for hepatocellular carcinoma. J Clin Gastroenterol (2011) 1.62

Impact of hepatitis B and C on graft loss and mortality of patients after kidney transplantation. Clin Transplant (2002) 1.60

Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients. J Hepatol (2011) 1.59

Noninvasive markers of liver fibrosis are highly predictive of liver-related death in a cohort of HCV-infected individuals with and without HIV infection. Am J Gastroenterol (2010) 1.56

Quantitation of pretreatment serum interferon-γ-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response. Hepatology (2011) 1.53

Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics. Hepatology (2004) 1.51

Differentiation and hematopoietic-support of clonal cells in myelodysplastic syndromes. Leuk Lymphoma (2007) 1.49

Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease. Clin Cancer Res (2008) 1.48

Single nucleotide polymorphism upstream of interleukin 28B associated with phase 1 and phase 2 of early viral kinetics in patients infected with HCV genotype 1. J Hepatol (2011) 1.47

Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology (2007) 1.40

Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C. Hepatology (2007) 1.38

Cutting edge: Compartmentalization of Th1-like noninvariant CD1d-reactive T cells in hepatitis C virus-infected liver. J Immunol (2002) 1.37

Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C. J Clin Pharmacol (2009) 1.37

A solid-state NMR study of phospholipid-cholesterol interactions: sphingomyelin-cholesterol binary systems. Biophys J (2002) 1.35

Progression of fibrosis in hepatitis C with and without schistosomiasis: correlation with serum markers of fibrosis. Hepatology (2006) 1.30

Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology (2004) 1.30

Rheology of gastric mucin exhibits a pH-dependent sol-gel transition. Biomacromolecules (2007) 1.29

Hepatic CD1d expression in hepatitis C virus infection and recognition by resident proinflammatory CD1d-reactive T cells. J Immunol (2004) 1.27

Diagnosing fibrosis in hepatitis C: is the pendulum swinging from biopsy to blood tests? Hepatology (2003) 1.27

Cellular immune responses in seronegative sexual contacts of acute hepatitis C patients. J Virol (2004) 1.25

Progression of fibrosis in advanced chronic hepatitis C: evaluation by morphometric image analysis. Hepatology (2007) 1.23

Human T cell microparticles circulate in blood of hepatitis patients and induce fibrolytic activation of hepatic stellate cells. Hepatology (2010) 1.20

Comparison of HCV-specific intrahepatic CD4+ T cells in HIV/HCV versus HCV. Hepatology (2004) 1.19

Biopsy or biomarkers: is there a gold standard for diagnosis of liver fibrosis? Clin Chem (2004) 1.13

Ultrasound-based hepatic elastography: origins, limitations, and applications. J Clin Gastroenterol (2010) 1.12

Kinetics of intrahepatic hepatitis C virus (HCV)-specific CD4+ T cell responses in HCV and Schistosoma mansoni coinfection: relation to progression of liver fibrosis. J Infect Dis (2004) 1.12

Atomic force microscopy reveals aggregation of gastric mucin at low pH. Biomacromolecules (2005) 1.11

Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring. Ann Hematol (2010) 1.11

Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. J Hepatol (2011) 1.09

EUS-guided liver biopsy: a procedure looking for an indication. Gastrointest Endosc (2009) 1.08

Circulating microparticles as disease-specific biomarkers of severity of inflammation in patients with hepatitis C or nonalcoholic steatohepatitis. Gastroenterology (2012) 1.06

Rapid and simple detection of IFN-neutralizing antibodies in chronic hepatitis C non-responsive to IFN-alpha. J Med Virol (2006) 1.03

Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial. Hepatology (2013) 1.03

Viscoelastic properties and dynamics of porcine gastric mucin. Biomacromolecules (2005) 1.01

Management of hepatitis C virus in special populations: patient and treatment considerations. Clin Gastroenterol Hepatol (2005) 1.01

Validation of hepascore, compared with simple indices of fibrosis, in patients with chronic hepatitis C virus infection in United States. Clin Gastroenterol Hepatol (2009) 0.99

Clinical utility of interleukin-28B testing in patients with genotype 1. Hepatology (2012) 0.98

Therapeutic strategies for chronic hepatitis B virus infection in 2008. Am J Med (2008) 0.98

Sustained long-term antiviral maintenance therapy in HCV/HIV-coinfected patients (SLAM-C). J Acquir Immune Defic Syndr (2010) 0.97

Eph receptor tyrosine kinase-mediated formation of a topographic map in the Drosophila visual system. J Neurosci (2002) 0.97

Correlation of FIBROSpect II with histologic and morphometric evaluation of liver fibrosis in chronic hepatitis C. Clin Gastroenterol Hepatol (2008) 0.97

Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia. Ann Hematol (2012) 0.96

Health care quality measurement in the care of patients with cirrhosis. Clin Gastroenterol Hepatol (2010) 0.96

Editorial: staging liver fibrosis in hepatitis C: a challenge for this decade. Am J Gastroenterol (2011) 0.95

Genetic analysis of cholesterol gallstone formation: searching for Lith (gallstone) genes. Curr Gastroenterol Rep (2004) 0.95

Biopsy no more; changing the screening and diagnostic algorithm for hepatitis C. Clin Gastroenterol Hepatol (2012) 0.94

CD8+ cell responses to hepatitis C virus (HCV) in the liver of persons with HCV-HIV coinfection versus HCV monoinfection. J Infect Dis (2005) 0.94

The challenge of developing novel pharmacological therapies for non-alcoholic steatohepatitis. Liver Int (2010) 0.94

A phase III study of the safety and efficacy of viramidine versus ribavirin in treatment-naïve patients with chronic hepatitis C: ViSER1 results. Hepatology (2009) 0.93

Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients. Hepatology (2009) 0.92

Differences in the disposition of silymarin between patients with nonalcoholic fatty liver disease and chronic hepatitis C. Drug Metab Dispos (2011) 0.92

Evaluation of serum biomarkers of fibrosis and injury in Egyptian patients with chronic hepatitis C. J Hepatol (2007) 0.91

Overexpression of estrogen receptor alpha increases hepatic cholesterogenesis, leading to biliary hypersecretion in mice. J Lipid Res (2005) 0.91

Efficacy and safety of CHG regimen (low-dose cytarabine, homoharringtonine with G-CSF priming) as induction chemotherapy for elderly patients with high-risk MDS or AML transformed from MDS. J Cancer Res Clin Oncol (2011) 0.89

Stability of liver fibrosis among HCV-infected injection drug users. Antivir Ther (2012) 0.89

An in situ molecular signature to predict early recurrence in hepatitis B virus-related hepatocellular carcinoma. J Hepatol (2012) 0.88

Estrogen receptor alpha, but not beta, plays a major role in 17beta-estradiol-induced murine cholesterol gallstones. Gastroenterology (2004) 0.87

Incidence and predictors of acute kidney injury in an urban cohort of subjects with HIV and hepatitis C virus coinfection. AIDS Patient Care STDS (2011) 0.87

Lith genes and genetic analysis of cholesterol gallstone formation. Gastroenterol Clin North Am (2010) 0.86

Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome. Leuk Lymphoma (2009) 0.86

Structural proteins of Hepatitis C virus induce interleukin 8 production and apoptosis in human endothelial cells. J Gen Virol (2005) 0.86

Targeted disruption of the murine mucin gene 1 decreases susceptibility to cholesterol gallstone formation. J Lipid Res (2004) 0.86

Technology evaluation: a critical step in the clinical utilization of novel diagnostic tests for liver fibrosis. J Hepatol (2007) 0.85

Serum biomarkers and transient elastography as predictors of advanced liver fibrosis in a United States cohort: the Boston children's hospital experience. J Pediatr (2013) 0.84

Lack of the intestinal Muc1 mucin impairs cholesterol uptake and absorption but not fatty acid uptake in Muc1-/- mice. Am J Physiol Gastrointest Liver Physiol (2004) 0.84

Natural history of carotid artery occlusion. Ann Vasc Surg (2012) 0.84